



3.2.1 Research on Invasive Clinical Cardiology - ICCI-PAZ Group

Publications: 73

Impact Factor: 1273.³⁴³

Q1: 27



Research Activity

Publications

- Argos CM, Fernández TL, López CV. Severe stenosis due to prosthetic thrombosis evaluated with TrueVue. *Rev Esp Cardiol.* 2020; 73(6): 499. Editorial Material. IF: 4.753; Q2
- Arribas F, Brugada J, Almendral J, Arbelo E, Infante ED, García-Cosío F, Lospitao S, Merino JL, Ormaetxe JM, Osca J, Tercedor L, Pedrote A, Lahuerta AA, Barón G, Escobar C, Fiol M, Fortuny E, Torrecilla EG, Font ER, Granel RR, Arribas F, Congost GB, Bueno H, Evangelista A, Ferreira-González I, Navarro MJ, Marín F, de Isla LP, Sambola A, Vazquez R, Viana-Tejedor A, Ibanez B, Alfonso F. Comments on the 2019 ESC guidelines on supraventricular tachycardia. *Rev Esp Cardiol.* 2020; 73(6): 445-51. Editorial Material. IF: 4.753; Q2
- Arroyo-Ucar E, Gómez RM, Vazquianez MR, Saura FT. Quo vadis, coronary lithoplasty. *Rev Esp Cardiol.* 2020; 73(5): 430. Letter. IF: 4.753; Q2
- Barrios V, Cosín-Sales J, Bravo M, Escobar C, Gámez JM, Huelmos A, Cortes CO, Egocheaga I, García-Pinilla JM, Jiménez-Candil J, López-de-Sa E, Llergo JT, Obaya JC, Pallares-Carratala V, Sanmartín M, Vidal-Pérez R, Cequier A. Telemedicine consultation for the clinical cardiologists in the era of COVID-19: present and future. Consensus document of the Spanish Society of

Cardiology. *Rev Esp Cardiol.* 2020; 73(11): 910-8. Article. IF: 4.753; Q2

- Barrios V, Escobar C. Reply to 'On the quality of life questionnaires in atrial fibrillation'. *Rev Clin Esp.* 2020; 220(2): 146-7. Letter. IF: 1.556; Q3
- Barrios V, Escobar C. Atrial fibrillation, an equivalent of cardiovascular disease risk. *Eur Heart J.* 2020; 41(48): 4599. Editorial Material. IF: 29.983; D1
- Barrios V, Escobar C. May we apply results data from classical hypertension clinical trials to all beta-blockers?. *J Hypertens.* 2020;38(12):- . Letter. IF: 4.844; Q2
- Barrios V, Escobar C, Arrarte V, García E, Fernández MR, Rincón LM, Roldán C. First national registry on the effectiveness and safety of evolocumab in clinical practice in patients attended in cardiology in Spain. The RETOSS-CARDIO study. *Clin Investig Arterioscler.* 2020; 32(6): 231-41. Article. Not indexed
- Barrios V, Escobar C, Arrarte V, Roldán C. First national registry of evolocumab in clinical practice in cardiology units in Spain. The RETOSS-CARDIO study. *Rev Esp Cardiol.* 2020; 73(6): 513-5. Letter. IF: 4.753; Q2
- Barrios V, Escobar C, Barón G, Gómez-Doblás J, Recalde E, Segura L, Álvarez P, Alonso F, Toril J, Chopo JM. Quality of life, medication adherence

and satisfaction with anticoagulant treatment (dabigatran vs vitamin K antagonists) according to thromboembolic risk. Data from the CAPANA study. *Int J Clin Pract.* 2020; 74(11): e13605. Letter. IF: 2.503; Q2

- Barrios V, Escobar C, Cortes CO, Sales JC, Figal DAP, Marimón XGM. Management of patients with heart failure treated in cardiology consultations: IC-BERG Study. *Rev Clin Esp.* 2020; 220(6): 339-49. Article. IF: 1.556; Q3
- Barrios V, Escobar C, Gómez-Doblas JJ, Fernández-Dueñas J, Garrido RR, Rodríguez JP, Sánchez JU, Arellano-Rodrigo E, Donado E. Patients' perceptions with dabigatran in patients with atrial fibrillation previously treated with vitamin K antagonists. *J Comp Eff Res.* 2020; 9(9): 615-25. Article. IF: 1.744; Q4
- Biscaglia S, Guiducci V, Santarelli A, Santos IA, Fernández-Avilés F, Lanzilotti V, Varbella F, Fileti L, Moreno R, Giannini F, Colaiori I, Menozzi M, Redondo A, Ruozzi M, Ibanes EG, Gil JLD, Maietti E, Zoccai GB, Escaned J, Tebaldi M, Barbato E, Dudek D, Colombo A, Campo G. Physiology-guided revascularization versus optimal medical therapy of nonculprit lesions in elderly patients with myocardial infarction: Rationale and design of the FIRE trial. *Am Heart J.* 2020; 229: 100-9. Article. IF: 4.479; Q2
- Bonadad Lozano C, Díez-Villanueva P, Blas SG,

Ayesta A, Ibars S, Ariza-Sole A, Ferreiro JL, Moreno R, Roldán I, Marín F, Carol Ruiz A, García Pardo H, Sanchis J, Cruz-González I, Anguita M, Cequier A, Ruiz García J, Martínez-Selles M. Impact of antithrombotic treatment and geriatric syndromes in octogenarians with atrial fibrillation and ischaemic heart disease. *Atrial Fibrillation and Ischemic Heart Disease in the Elderly. Rev Esp Geriatr Gerontol.* 2020; 55(6): 338-42. Article. Not indexed

- Cantor WJ, Lavi S, Dzavik V, Cairns J, Cheema AN, Della Siega A, Moreno R, Stankovic G, Kede S, Natarajan MK, Levi Y, Yuan F, Jolly SS. Upstream anticoagulation for patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Insights from the TOTAL trial. *Catheter Cardio Inte.* 2020; 96(3): 519-25. Article. IF: 2.692; Q3
- Celutkienė J, Pudil R, López-Fernández T, Grapsa J, Nihoyannopoulos P, Bergler-Klein J, Cohen-Solal A, Farmakis D, Tocchetti CG, von Haehling S, Barberis V, Flachskampf FA, Ceponiene I, Haegler-Laube E, Suter T, Lapinskas T, Prasad S, de Boer RA, Wechalekar K, Anker MS, Iakobishvili Z, Bucciarelli-Ducci C, Schulz-Menger J, Cosyns B, Gaemperli O, Belenkov Y, Hulot JS, Galderisi M, Lancellotti P, Bax J, Marwick TH, Chioncel O, Jansma T, Mullens W, Piepoli M, Thum T, Heymans S, Mueller C, Moura B, Ruschitzka F, Zamorano




3.2 Cardiovascular Area

- JL, Rosano G, Coats AJS, Asteggiano R, Seferovic P, Edvardsson T, Lyon AR. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). *Eur J Heart Fail*. 2020; 22(9): 1504-24. Article. IF: 15.534; D1
- Chieffo A, Stefanini GG, Price S, Barbato E, Tarantini G, Karam N, Moreno R, Buchanan GL, Gilard M, Halvorsen S, Huber K, James S, Neumann FJ, Mollmann H, Roffi M, Tavazzi G, Ferre JM, Windecker S, Dudek D, Baumbach A. EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic. *Eurointervention*. 2020; 16(3): 233-46. Article. IF: 6.534; Q1
 - Chieffo A, Stefanini GG, Price S, Barbato E, Tarantini G, Karam N, Moreno R, Buchanan GL, Gilard M, Halvorsen S, Huber K, James S, Neumann FJ, Mollmann H, Roffi M, Tavazzi G, Ferre JM, Windecker S, Dudek D, Baumbach A. EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic. *Eur Heart J*. 2020; 41(19): 1839-51. Article. IF: 29.983; D1
 - Dangas GD, Tijssen JGP, Wöhrle J, Sondergaard L, Gilard M, Mollmann H, Makkar RR, Herrmann HC, Giustino G, Baldus S, De Backer O, Guimaraes AHC, Gullestad L, Kini A, von Lewinski D, Mack M, Moreno R, Schafer U, Seeger J, Tchetche D, Thomitzek K, Valgimigli M, Vranckx P, Welsh RC, Wildgoose P, Volk AA, Zazula A, van Amsterdam RGM, Mehran R, Windecker S. A Controlled trial of rivaroxaban after transcatheter aortic-valve replacement. *New Engl J Med*. 2020; 382(2): 120-9. Article. IF: 91.245; D1
 - De Luca G, Cercek M, Jensen LO, Vavlukis M, Calmac L, Johnson T, Ferrer GRI, Ganyukov V, Wojakowski W, van Birgelen C, Versaci F, Ten Berg J, Laine M, Dirksen M, Casella G, Kala P, Gil JLD, Becerra V, De Simone C, Carrillo X, Scoccia A, Lux A, Kovarnik T, Davlouros P, Gabrielli G, Rios XF, Bakracski N, Levesque S, Guiducci V, Kidawa M, Marinucci L, Zilio F, Galasso G, Fabris E, Menichelli M, Manzo S, Caiazzo G, Moreu J, Fores JS, Donazzan L, Vignali L, Teles R, Ojeda FB, Lehtola H, Camacho-Freire S, Kraaijeveld A, Antti Y, Boccanlatte M, Martínez-Luengas IL, Scheller B, Alexopoulos D, Uccello G, Faurie B, Barrios AG, Wilbert B, Cortese G, Moreno R, Parodi G, Kedhi E, Verdoia M. Impact of COVID-19 pandemic and diabetes on mechanical reperfusion in patients with STEMI: insights from the ISACS STEMI COVID 19 Registry. *Cardiovasc Diabetol*. 2020; 19(1): 215. Article. IF: 9.951; D1
 - De Luca G, Verdoia M, Cercek M, Jensen LO, Vavlukis M, Calmac L, Johnson T, Ferrer GR, Ganyukov V, Wojakowski W, Kinnaird T, van Birgelen C, Cottin Y, IJsselmuiden A, Tuccillo B, Versaci F, Royakkers KJ, Ten Berg J, Laine M, Dirksen M, Siviglia M, Casella G, Kala P, Gil JLD, Banning A, Becerra V, De Simone C, Santucci A, Carrillo X, Scoccia A, Amoroso G, Lux A, Kovarnik T, Davlouros P, Mehili J, Gabrielli G, Rios XF, Bakracski N, Levesque S, Cirrincione G, Guiducci V, Kidawa M, Spedicato L, Marinucci L, Ludman P, Zilio F, Galasso G, Fabris E, Menichelli M, García-Touchard A, Manzo S, Caiazzo G, Moreu J, Fores JS, Donazzan L, Vignali L, Teles R, Benit E, Agostoni P, Ojeda FB, Lehtola H, Camacho-Freire S, Kraaijeveld A, Antti Y, Boccanlatte M, Deharo P, Martínez-Luengas IL, Scheller B, Alexopoulos D, Moreno R, Kedhi E, Uccello G, Faurie B, Barrios AG, Di Uccio FS, Wilbert B, Smits P, Cortese G, Parodi G, Dudek D. Impact of COVID-19 Pandemic on Mechanical Reperfusion for Patients With STEMI. *J Am Coll Cardiol*. 2020; 76(20): 2321-30. Article. IF: 24.094; D1
 - Divison-Garrote JA, Prieto-Diaz MA, Alonso-Moreno FJ, Velilla-Zancada SM, Escobar-Cervantes C, Llisterri-Caro JL, Cinza-Sanjurjo S, Rodríguez-Roca GC, Polo-García J, Pallares-Carratala V. Prevalence of hypotension in hypertensive treated patients within the Primary Care setting. The PRESCAP 2010 study. *Semergen*. 2020; 46(2): 107-14. Article. Not Indexed
 - Escobar C, Anguita M, Arrarte V, Barrios V, Cequier A, Cosin-Sales J, Egocheaga I, de Sa EL, Masana L, Pallares V, de Isla LP, Pinto X, Juanatey JRG, Zamorano JL. Recommendations to improve lipid control. Consensus document of the Spanish Society of Cardiology. *Rev Esp Cardiol*. 2020; 73(2): 161. Article. IF: 4.753; Q2
 - Escobar C, Borrás X, Freire RB, González-Juanatey C, Morillas M, Muñoz AV, Gómez-Doblas JJ. A Delphi consensus on the management of oral anticoagulation in patients with nonvalvular atrial fibrillation in Spain: ACOPREFERENCE study. *Plos One*. 2020; 15(6): e0231565. Article. IF: 3.24; Q2
 - Escobar C, Varela L, Palacios B, Capel M, Sicras A, Sicras A, Hormigo A, Alcazar R, Manito N, Botana M. Costs and healthcare utilisation of patients with heart failure in Spain. *Bmc Health Serv Res*. 2020; 20(1): 964. Article. IF: 2.655; Q3
 - Ezhov MV, Catapano A, Escobar C, Kukharchuk VV, Voevoda MI, Drapkina OM, Shalnova SA, Starodubova AV, Gurevich VS, Shaposhnik II, Bolsakova OO, Oynotkinova OS, Alieva AS. The role of red yeast rice based preparations for non-pharmacological correction of dyslipidemia in patients with low and moderate cardiovascular risk (Expert Opinion). *Ration Pharmacother Cardiol*. 2020; 16(1): 147-55. Article. Not Indexed
 - Farkowski MM, Jubele K, Marin F, Gandjbakhch E, Ptaszynski P, Merino JL, Lenarczyk R, Potpara TS. Diagnosis and management of left atrial appendage thrombus in patients with atrial fibrillation undergoing cardioversion or percutaneous left atrial procedures: results of the European Heart Rhythm Association survey. *Eurpace*. 2020; 22(1): 162-9. Article. IF: 5.214; Q2
 - Gaitán RM, Vicent L, Rodríguez-Queraltó O, López-de-Sa E, Elorriaga A, Pastor G, Baneras J, Lorenzo B, García-Rubira JC, Corbi M, Ariza A, Martínez-Selles M. Dexmedetomidine in medical cardiac intensive care units. Data from a multicenter prospective registry. *Int J Cardiol*. 2020; 310: 162-6. Article. IF: 4.164; Q2
 - Goette A, Lip GYH, Jin J, Heidbuchel H, Cohen AA, Ezekowitz M, Merino JL. Differences in thromboembolic complications between paroxysmal and persistent atrial fibrillation patients following electrical cardioversion (From the ENSURE-AF Study). *Am J Cardiol*. 2020; 131: 27-32. Article. IF: 2.778; Q3
 - Goette A, Merino JL, De Caterina R, Huber K, Heidbuchel H, Jin J, Lip GYH. Effect of concomitant antiplatelet agents on clinical outcomes in the edoxaban vs warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomized trial. *Clin Res Cardiol*. 2020; 109(11): 1374-80. Article. IF: 5.46; Q1
 - González-García A, Hernández-Matamoros H, Jiménez-Valero S, Jurado-Román A, Galeote G, Moreno R, López-Sendón JL. Coronary thrombosis from superficial calcific sheet. *J Invasive Cardiol*. 2020; 32(10): E266. Editorial Material. IF: 2.022; Q3
 - González-García A, Hernández-Matamoros H, Jurado-Román A, Galeote G, Jiménez-Valero S, Moreno R. Valve in valve procedure and left main stent: To deliver or not to deliver. *Cardiol J*. 2020; 27(1): 87-8. Editorial Material. IF: 2.737; Q3
 - González-García A, Jurado-Román A, Hernández-Matamoros H, Jiménez-Valero S, Galeote G, Moreno R, López-Sendón JL. Iatrogenic atrial septal defect after percutaneous mitral valve repair with MitraClip: Should we consider closing them routinely? *J Invasive Cardiol*. 2020; 32(11): E295-7. Article. IF: 2.022; Q3
 - Gutiérrez GG, Díaz-Manera J, Almendrote M, Azriel S, Barcena JE, García PC, Salas AC, Rodríguez CC, Cobo AM, Guardiola PD, Fernández-Torrón R, Petit MPG, Pavia PG, Gallego MG, Martínez AJG, Jerico I, García SK, Arregui ALD, Martorell L, de la Tassa GM, Zabaleta RM, Muñoz-Blanco JL, Roldán JO, Pascual SIP, Peinado RP, Pérez H, Aldea JJP, Rabasa M, Ramos A, Bartolome AR, Pérez MAR, Urtizberea JA, Zapata-Wainberg G, Gutiérrez-Rivas E. Clinical guide for the diagnosis and follow-up of myotonic dystrophy type 1, MD1 or Steinert's disease. *Neurología*. 2020; 35(3): 185-206. Article. IF: 3.109; Q3
 - Hernández JMD, Camarero TG, Alonso JAB, Gómez-Hospital JA, Fernández GV, Hwang DHL, Laso FS, Recalde AS, de Prado AP, Martínez-Luengas IL, Hernández FH, Lizarbe SG, Alonso LG, Zueco J, Alfonso F. Outcomes of predefined optimisation criteria for intravascular ultrasound guidance of left main stenting. *Eurointervention*. 2020; 16(3): 210-7. Article. IF: 6.534; Q1
 - Hijazi Z, Granger CB, Hohnloser SH, Westerberg J, Lindback J, Alexander JH, Keltai M, Parkhomenko A, López-Sendón JL, Lopes RD, Siegbahn A, Wallentin L. Association of different estimates of renal function with cardiovascular mortality and bleeding in atrial fibrillation. *J Am Heart Assoc*. 2020; 9(18): e017155. Article. IF: 5.501; Q1



3.2 Cardiovascular Area

- Íñiguez A, Chevalier B, Richardt G, Neylon A, Jiménez VA, Kornowski R, Carrie D, Moreno R, Barbato E, Serra-Penaranda A, Guiducci V, Valdés-Chavarri M, Yajima J, Wijns W, Saito S. Comparison of long-term clinical outcomes in multi-vessel coronary artery disease patients treated either with bioresorbable polymer sirolimus-eluting stent or permanent polymer everolimus-eluting stent: 5-year results of the CENTURY II randomized clinical trial. *Catheter Cardio Inte*. 2020; 95(2): 175-84. Article. IF: 2.692; Q3
- Jurado-Román A, Hernández H, Jiménez-Valero S, Martín-Polo L, Galeote G, González A, Moreno R, López-Sendón JL. Coronary perforation after excimer laser coronary angioplasty at a calcium nodule. *J Invasive Cardiol*. 2020; 32(8): E226-7. Editorial Material. IF: 2.022; Q3
- Jurado-Román A, Jiménez-Valero S, Galeote G, Moreno R, López-Sendón JL. Very long-term outcome of coronary covered stents. Not all covered stents are the same. *Eurointervention*. 2020;15(14):1297-1297. Letter. IF: 6.534; Q1
- Kontny F, Andersen T, Ueland T, Akerblom A, Lakic TG, Michelsen AE, Aukrust P, Bertils-son M, Becker RC, Himmelmann A, James SK, Siegbahn A, Storey RF, Wallentin L. Pentraxin-3 vs C-reactive protein and other prognostic biomarkers in acute coronary syndrome: A substudy of the Platelet Inhibition and Patients Outcomes (PLATO) trial. *Eur Heart J Acute Cardiovasc Care*. 2020; 9(4): 313-22. Article. IF: 4.696; Q2
- Kozziel M, Merino JL, de Caterina R, Huber K, Jin JM, Melino M, Goette A, Lip GYH. Comparing TEE- vs Non-TEE-guided cardioversion of atrial fibrillation: The ENSURE-AF trial. *Eur J Clin Invest*. 2020; 50(5): e13221. Article. IF: 4.686; Q1
- Lenihan D, Carver J, Porter C, Liu JE, Dent S, Thavendiranathan P, Mitchell JD, Nohria A, Fradley MG, Pusic I, Stockerl-Goldstein K, Blaes A, Lyon AR, Ganatra S, López-Fernández T, O'Quinn R, Minotti G, Szmit S, Cardinale D, Alvarez-Cardona J, Curigliano G, Neilan TG, Herrmann J. Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement. *Ca-Cancer J Clin*. 2020; 70(6): 480-504. Article. IF: 508.702; D1
- Lopes RD, Alexander KP, Stevens SR, Reynolds HR, Stone GW, Pina IL, Rockhold FW, Elghamazy A, López-Sendón JL, Farsky PS, Chernyavsky AM, Diaz A, Phaneuf D, De Belder MA, Ma YT, Guzmán LA, Khouri M, Sionis A, Hausenloy DJ, Doerr R, Selvanayagam JB, Maggioni AP, Hochman JS, Maron DJ. Initial invasive versus conservative management of stable ischemic heart disease in patients with a history of heart failure or left ventricular dysfunction insights from the ISCHEMIA trial. *Circulation*. 2020; 142(18): 1725-35. Article. IF: 29.69; D1
- López-Fernández T. Cardiac imaging in oncology patients in Europe: a model for advancement of CV safety and development of comprehensive CV care. *J Cardiovasc Transl*. 2020; 13(3): 490-4. Review. IF: 4.132; Q2
- López-Fernández T, López-Sendón JL. Heart failure after treatment for breast cancer: old cancer therapies, new clinical data. What do we need to complete the puzzle? *Eur J Heart Fail*. 2020; 22(2): 375-7. Editorial Material. IF: 15.534; D1
- López-Honrubia V, Hidalgo-Olivares VM, Dobon-Roux M, Martí-Laosa MM, Castro-Larefors S, Fernández-Lopee J, Andrés I, Roche O, Rovirasa A, Arenas M, Martínez-Terol F, Fernández TL, Sabater S. Radiotherapy is safe in patients with implantable cardiac devices. Analysis of a systematic interrogation follow-up. *Clin Transl Oncol*. 2020; 22(12): 2286-92. Article. IF: 3.405; Q3
- López-Mínguez JR, Nogales-Asensio JM, De Oliveira EI, Santos L, Ruiz-Salmeron R, Arzamendi-Aizpurua D, Costa M, Gutiérrez-García H, Fernández-Díaz JA, Freixa X, Cruz-González I, Moreno R, Iniguez-Romo A, Alfonso-Manterola F. Major bleeding predictors in patients with left atrial appendage closure: The Iberian Registry II. *J Clin Med*. 2020; 9(7): 2295. Article. IF: 4.241; Q1
- López-Sendón J, Álvarez-Ortega C, Auñón PZ, Soto AB, Lyon AR, Farmakis D, Cardinale D, Al-bendea MC, Batlle JF, Rodríguez IR, Fraga OR, Albaladejo A, Mediavilla G, González-Juanatey JR, Monzonis AM, Prieto PG, González-Costello J, Antolin JMS, Chamorro RC, Fernández TL. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. *Eur Heart J*. 2020; 41(18): 1720-+. Article. IF: 29.983; D1
- Lucas MF, Ruiz-Roso G, Merino JL, Sánchez R, Bouarich H, Herrero JA, Muriel A, Zamora J, Collado A. Initiating renal replacement therapy through incremental haemodialysis: Protocol for a randomized multicentre clinical trial. *Trials*. 2020; 21(1): 206. Article. IF: 2.279; Q4
- Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, Tocchetti CG, Moslehi JJ, Groarke JD, Bergler-Klein J, Khoo V, Tan LL, Anker MS, von Haehling S, Maack C, Pudil R, Barac A, Thavendiranathan P, Ky B, Neilan TG, Belenkav Y, Rosen SD, Iakobishvili Z, Sverdlav AL, Hajjar LA, Macedo AVS, Manisty C, Ciardiello F, Farmakis D, de Boer RA, Skouri H, Suter TM, Cardinale D, Witteles RM, Fradley MG, Herrmann J, Cornell RF, Wechelaker A, Mauro MJ, Milojko-





3.2 Cardiovascular Area

- vic D, de Lavallade H, Ruschitzka F, Coats AJS, Seferovic PM, Chioncel O, Thum T, Bauersachs J, Andres MS, Wright DJ, López-Fernández T, Plummer C, Lenihan D. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. *Eur J Heart Fail.* 2020 ;22(11): 1945-60. Article. IF: 15.534; D1
- Manolis AJ, Kallistratos MS, Poulimenos LE, Ambrosio G, Dechend R, López-Sendón J, Rosano G, Collins P. The ESC 2019 CCS guidelines: Have we left our patients and scientific evidence behind? *Eur J Intern Med.* 2020; 72: 5-8. Review. IF: 4.487; Q1
 - Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O'Brien SM, Boden WE, Chaitman BR, Senior R, López-Sendón J, Alexander KP, Lopes RD, Shaw LJ, Berger JS, Newman JD, Sidhu MS, Goodman SG, Ruzyllo W, Gosselin G, Maggioni AP, White HD, Bhargava B, Min JK, Mancini GBJ, Berman DS, Picard MH, Kwong RY, Ali ZA, Mark DB, Spertus JA, Krishnan MN, Elghamazi A, Moorthy N, Hueb WA, Demkow M, Mavromatis K, Bockeria O, Peteiro J, Miller TD, Szwed H, Doerr R, Keltai M, Selvanayagam JB, Steg PG, Held C, Kohsaka S, Mavromichalis S, Kirby R, Jeffries NO, Harrell FE, Rockhold FW, Broderick S, Ferguson TB, Williams DO, Harrington RA, Stone GW, Rosenberg Y. Initial invasive or conservative strategy for stable coronary disease. *New Engl J Med.* 2020; 382(15): 1395-407. Article. IF: 91.245; D1
 - Martínez-Losas P, de Sa EL, Armada E, Rosillo S, Monedero MC, Rey JR, Caro-Codon J, Soto AB, Sendón JPLL. Neuron-specific enolase kinetics: an additional tool for neurological prognostication after cardiac arrest. *Rev Esp Cardiol.* 2020; 73(2): 123-30. Article. IF: 4.753; Q2
 - Martín-García A, López-Fernández T, Mitroi C, Chaparro-Munoz M, Moliner P, Martín-García AC, Martínez-Monzonis A, Castro A, López-Sendón JL, Sánchez PL. Effectiveness of sacubitril-valsartan in cancer patients with heart failure. *Esc Heart Fail.* 2020; 7(2): 763-7. Article. IF: 4.411; Q2
 - Merino JL, Martínez-Cossiani M, Iniesta A, Escobar C, Rey JR, Castrejón-Castrejón S. COVID-19 and QT interval prolongation: more than just drug toxicity? *Europace.* 2020; 22(10): 1479. Editorial Material. IF: 5.214; Q2
 - Ojeda S, Romaguera R, Cruz-González I, Moreno R. Spanish cardiac catheterization and coronary intervention registry. 29th Official Report of the Interventional Cardiology Association of the Spanish Society of Cardiology (1990-2019). *Rev Esp Cardiol.* 2020; 73(11): 927-36. Article. IF: 4.753; Q2
 - Pascual-Tejerina V, Sánchez-Recalde A, Cantador JR, González AE, Gutiérrez-Larraya F, Oliver JM. Long-term follow-up of patients with repaired coarctation of the aorta who develop hemoptysis. *Rev Esp Cardiol.* 2020; 73(3): 265-7. Letter. IF: 4.753; Q2
 - Quevedo PJ, Pan M, Moreno R, de Prado AP. Scientific evidence versus expert opinion. Should we modify clinical practice guidelines? *Rev Esp Cardiol.* 2020; 73(2): 187-9. Letter. IF: 4.753; Q2
 - Refoyo E, Troya J, Trigo E, Guzmán-Martínez G, Valbuena-López S, Caro-Codon J, Rosillo S, Moreno-Yanguela M, Tamargo J, Arribas JR, Acquatella H, López-Sendón J. Comparison of noninvasive cardiac test strategies for newly diagnosed chagas disease in a non-endemic zone. *Am J Trop Med Hyg.* 2020; 103(4): 1480-6. Article. IF: 2.345; Q2
 - Rey JR, Caro-Codón J, Pineda DP, Merino JL, Iniesta AM, López-Sendón JL. Arterial thrombotic complications in hospitalized patients with COVID-19. *Rev Esp Cardiol.* 2020; 73(9): 769-71. Letter. IF: 4.753; Q2
 - Rey JR, Caro-Codón J, Sotelo LR, López-de-Sa E, Rosillo SO, Fernández OG, de Bobadilla JF, Iniesta AM, Conde LP, Miranda IA, Armada E, Cantador JR, López-Sendón JL. Long term clinical outcomes in survivors after out-of-hospital cardiac arrest. *Eur J Intern Med.* 2020; 74: 49-54. Article. IF: 4.487; Q1
 - Rey JR, Valero SJ, Pineda DP, Merino JL, López-Sendón JL, Caro-Codon J. COVID-19 and simultaneous thrombosis of two coronary arteries. *Rev Esp Cardiol.* 2020; 73(8): 676-8. Letter. IF: 4.753; Q2
 - Reynolds HR, Shaw LJ, Min JK, Spertus JA, Chaitman BR, Berman DS, Picard MH, Kwong RY, Bairey-Merz CN, Cyr DD, Lopes RD, López-Sendón JL, Held C, Szwed H, Senior R, Gosselin G, Nair RG, Elghamazi A, Bockeria O, Chen JY, Chernyavskiy AM, Bhargava B, Newman JD, Hinic SB, Jaroch J, Hoyer A, Berger J, Boden WE, O'Brien SM, Maron DJ, Hochman JS. Association of sex with severity of coronary artery disease, ischemia, and symptom burden in patients with moderate or severe ischemia secondary analysis of the ISCHEMIA randomized clinical trial. *Jama Cardiol.* 2020; 5(7): 773-86. Article. IF: 14.676; D1
 - Rodríguez-Leor O, Cid-Alvarez B, de Prado AP, Rossello X, Ojeda S, Serrador A, López-Palop R, Martín-Moreiras J, Rumoroso JR, Cequier A, Ibáñez B, Cruz-González I, Romaguera R, Moreno R. Impact of COVID-19 on ST-segment elevation myocardial infarction care. The Spanish experience. *Rev Esp Cardiol.* 2020; 73(12): 994-1002. Article. IF: 4.753; Q2
 - Sánchez-Salado JC, Burgos V, Ariza-Sol A, Sionis A, Canteli A, Bernal JL, Fernández C, Castrillo C, Ruiz-Lera M, López-de-Sa E, Lidon RM, Worner F, Martínez-Selles M, Segovia J, Viana-Tejedor A, Lorente V, Alegre O, Llaó I, González-Costello J, Manito N, Cequier A, Bueno H, Elola J. Trends in cardiogenic shock management and prognostic impact of type of treating center. *Rev Esp Cardiol.* 2020; 73(7): 546-53. Article. IF: 4.753; Q2
 - Sheth T, Pinilla-Echeverri N, Moreno R, Wang J, Wood DA, Storey RF, Mehran R, Bainey KR, Bossard M, Bangalore S, Schwalm JD, Velianou JL, Valettas N, Sibbald M, Rodes-Cabau J, Ducas J, Cohen EA, Bagai A, Rinfret S, Newby DE, Feldman L, Laster SB, Lang IM, Mills JD, Cairns JA, Mehta SR. Nonculprit lesion severity and outcome of revascularization in patients with STEMI and multivessel coronary disease. *J Am Coll Cardiol.* 2020; 76(11): 1277-86. Article. IF: 24.094; D1
 - Sicras-Mainar A, Escobar-Cervantes C, Mico-Pérez RM, Llisterri-Caro JL. Clinical and economic consequences in patients initiating therapy with clopidogrel brand-name vs. generic: A real-life retrospective study. *Semergen.* 2020; 46(1): 16-26. Article. Not indexed
 - Solano-López J, Zamorano JL, Sanz AP, Amat-Santos I, Sarnago F, Ibanes EG, Sanchis J, Blas JRR, Gómez-Hospital JA, Martínez SS, Maneiro-Melón NM, Gaitán RM, D'Gregorio JG, Salido L, Mestre JL, Sanmartín M, Sánchez-Recalde A. Risk factors for in-hospital mortality in patients with acute myocardial infarction during the COVID-19 outbreak. *Rev Esp Cardiol.* 2020; 73(12): 985-93. Article. IF: 4.753; Q2
 - Tyl B, Sendón JL, Borer JS, De Sa EL, Lerebours G, Varin C, De Montigny A, Pannaux M, Komajda M. Comparison of outcome adjudication by investigators and by a central end point committee in heart failure trials: experience of the SHIFT heart failure study. *Circ-Heart Fail.* 2020; 13(7): e006720. Article. IF: 8.79; Q1
 - Ueland T, Akerblom A, Ghukasyan T, Michelsen AE, Becker RC, Bertilsson M, Budaj A, Cornel JH, Himmelmann A, James SK, Siegbahn A, Storey RF, Kontny F, Aukrust P, Wallentin L, (López-Sendón JL). ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trial. *Atherosclerosis.* 2020; 293: 35-41. Article. IF: 5.162; Q2
 - Windecker S, Latib A, Kedhi E, Kirtane AJ, Kandzari DE, Mehran R, Price MJ, Abizaid A, Simon DI, Worthley SG, Zaman A, Hudec M, Poliacikova P, Gharap AKA, Selvaraj K, Petrov I, Mylotte D, Pinar E, Moreno R, Fabbicchi F, Pasupati S, Kim HS, Aminian A, Tie C, Włodarczak A, Hur SH, Marx SO, Jankovic I, Brar S, Bousquette L, Liu M, Stone GW. Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk. *New Engl J Med.* 2020; 382(13): 1208-18. Article. IF: 91.245; D1
 - Zamorano JL, Gottfridsson C, Asteggiano R, Atar D, Badimón L, Bax JJ, Cardinale D, Cardone A, Feijen EAM, Ferdinandy P, López-Fernández T, Gale CP, Maduro JH, Moslehi J, Omland T, Gómez JCP, Scott J, Suter TM, Minotti G. The cancer patient and cardiology. *Eur J Heart Fail.* 2020; 22(12): 2290-309. Review. IF: 15.534; D1
 - Zeitouni M, Giczewska A, Lopes RD, Wojdyla DM, Christersson C, Siegbahn A, De Caterina R, Steg PG, Granger CB, Wallentin L, Alexander JH. (López-Sendón JL). Clinical and pharmacological effects of apixaban dose adjustment in the ARISTOTLE Trial. *J Am Coll Cardiol.* 2020; 75(10): 1145-55. Article. IF: 24.094; D1



3.2 Cardiovascular Area

Research projects

Castro Conde A. Rehab+ [R+]. EIT-Health. 2020-2021.

Managment centre: FIBHULP

Galeote García G. Aterectomia rotacional electiva vs de rescate en pacientes con lesiones coronarias calcificadas graves e insuficiencia renal crónica. Boston Scientific International S. A. 2020-Ongoing.

Managment centre: FIBHULP

Guzmán Martínez G. Marcadores precoces de disfunción ventricular derecha y alteraciones de la circulación pulmonar en pacientes afectados de hipertensión pulmonar. Siemens HealthCare S. L. 2018-Ongoing.

Managment centre: FIBHULP

Jiménez Valero S. Análisis de correlación entre los marcadores de inflamación y morfología de placas coronarias mediante tomografía de coherencia óptica y tec multicorte: Estudio IVI. Abbott Laboratories S. A. 2009-Ongoing.

Managment centre: FIBHULP

Jiménez Valero S. Estudio en modelo porcino para evaluar la utilidad de la tomografía de coherencia óptica en el análisis de las lesiones endocárdicas producidas por radiofrecuencia. Medlumics S. L. 2015-Ongoing.

Managment centre: FIBHULP

López-Sendón Hentschel JL. Antorrena Miranda MI. Colchicine cardiovascular outcome trial. Montreal Heart Institute. 2017-Ongoing.

Managment centre: FIBHULP

López-Sendón Hentschel JL. Antorrena Miranda MI. Colchicine coronavirus Sars-Cov2 trial. Colcorona-COVID-19. Montreal Heart Institute. 2020-Ongoing.

Managment centre: FIBHULP

López-Sendón Hentschel JL. Antorrena Miranda MI. International study of compara-

tive health effectiveness with medical and invasive approaches. Estudio internacional comparativo de la eficacia sanitaria con enfoques médicos e invasivos. New York University School of Medicine. 2013-2021.

Managment centre: FIBHULP

López-Sendón Hentschel JL. Biomarcadores en la cardiotoxicidad por agentes anti-neoplás: rendimiento diagnóstico. Boehringer Ingelheim España S. A. 2015-Ongoing.

Managment centre: FIBHULP

López-Sendón Hentschel JL. Investigación traslacional en arritmias cardíacas hereditarias [S2017/BMD-3738]. CM. 2018-2021.

Managment centre: FIBHULP

Merino Llorens JL. Actividades formativas de investigación en cirugía cardíaca pediátrica. Magnetec Corp. 2006-Ongoing.

Managment centre: FIBHULP

Merino Llorens JL. Addressing multimorbidity in elderly atrial fibrillation patients through interdisciplinary, tailored, patient-centred care pathways (EHRA-PATHS). UE. 2020-2026.

Managment centre: FIBHULP

Merino Llorens JL. El vectorcardiograma como herramienta de caracterización no invasiva de la dinámica de activación y de I-A presencia y localización de zonas de conducción lenta en los circuitos de Flijer auricular atípico izquierdo mediante vectorcardiograma. Arrhythmia Network Technology S. L. 2018-Ongoing.

Managment centre: FIBHULP

Merino Llorens JL. Formación en investigación en electrofisiología cardíaca. European Society of Cardiology. 2015-Ongoing.

Managment centre: FIBHULP

Merino Llorens JL. High radiofrequency power for faster and safer pulmonary veins

ablation trial (Power FAST II) [PI18/01522]. ISCIII. 2019-2021.

Managment centre: FIBHULP

Merino Llorens JL. High radiofrequency power for fast and safe pulmonary veins ablation-a pilot observational study (Power Fast I). Arrhythmia Network Technology S. L. 2018-Ongoing.

Managment centre: FIBHULP

Merino Llorens JL. Hospital Smart development based on AI (HosmartAI). UE. 2020-2024.

Managment centre: FIBHULP

Merino Llorens JL. Innovación tecnológica en cardiología: mapas tridimensionales de ciclo de retorno para la ablación de taquicardias macroreentrantes. Medtronic Iberica S. A. 2007-Ongoing.

Managment centre: FIBHULP

Merino Llorens JL. Registro retrospectivo de identificación de factores cardiovasculares de mal pronóstico en pacientes COVID 19. Medtronic Iberica S. A. 2020-Ongoing.

Managment centre: FIBHULP

Moreno Gómez JR. Evaluación clínica y seguimiento de los pacientes con cardiopatía estructural sometidos a procedimientos de tratamiento percutáneo. Subproyecto: análisis de expresión de mirnas relacionados con el proceso angiogénico en cáncer mama. Abbott Laboratories S. A. 2011-Ongoing.

Managment centre: FIBHULP

Peinado Peinado R. Comparación de un cateter multielectrodo frente a un cateter de ablación de punta irrigada para crear mapas de voltaje y activación en pacientes con taquicardias auriculares macroreentrantes. Medtronic Iberica S. A. 2019-Ongoing.

Managment centre: FIBHULP

Peinado Peinado R. Influencia del remodelado eléctrico del miocardio auricular en la

recurrencia de fibrilación auricular tras el aislamiento eléctrico de las venas pulmonares por fibrilación auricular paroxística. Medtronic Iberica S. A. 2009-Ongoing.

Managment centre: FIBHULP

Peinado Peinado R. Registro de pacientes con cardiopatía congénita del adulto portadores de un sistema de terapia de resincronización cardíaca (RETRACCA). Medtronic Iberica S. A. 2017-Ongoing.

Managment centre: FIBHULP

Peinado Peinado R. Síndrome de apneas-hipopneas obstructivas del sueño y arritmias ventriculares en pacientes con disfunción ventricular sistólica portadores de DAI. Fundación Casa del Corazón. 2008-Ongoing.

Managment centre: FIBHULP

Peinado Peinado R. Utilidad de los algoritmos de diagnóstico diferencial electrocardiográfico de las taquicardias regulares de QRS ancho en pacientes con cardiopatías congénitas de adulto. Medtronic Iberica S. A. 2019-Ongoing.

Managment centre: FIBHULP

Riera del Moral LF. Tratamiento celular de los aneurismas de aorta abdominal en un modelo murino. Riera del Moral, Luis Felipe. 2017-Ongoing.

Managment centre: FIBHULP

Clinical trials

Antorrena Miranda, MI. Detección precoz de isquemia miocárdica compatible con síndrome coronario agudo mediante APO J-GLYC como un nuevo biomarcador de isquemia.

Type: Estudios, phase No EPA.

HULP code: Anexo 3 PI-3647.

Sponsored's protocol code: EDICA-2019.

Sponsored by: Glycardial Diagnostics S.L.

Signed date: 23/09/2020



3.2 Cardiovascular Area

Antorrena Miranda, MI. Ensayo de colchicina en el SARS-COV2 coronavirus (Colcorona-covid-19).

Type: EECC, phase III.

HULP code: 5578.

Sponsored's protocol code:

MHIPS-2020-01 COLCORONA.

Sponsored by: FIBHULP.

Signed date: 01/06/2020

Antorrena Miranda, MI. Estudio observacional para evaluar el beneficio clínico neto de edoxaban en pacientes con fibrilación auricular no valvular, según práctica clínica habitual en España. Registro Benefit.

Type: Estudios, phase EPA-OD.

HULP code: PI-4283.

Sponsored's protocol code: DSE-

EDO-2020-01.

Sponsored by: Daiichi Sankyo España.

Signed date: 13/11/2020

Castro Conde, A. Comparación del efecto de tirzepatida frente al de dulaglutida sobre los acontecimientos cardiovasculares mayores en pacientes con diabetes de tipo 2 (Surpass-CVOT).

Type: EECC, phase I.

HULP code: 5484.

Sponsored's protocol code: 18F-MC-GPGN.

Sponsored by: Lilly S.A.

Signed date: 29/01/2020

Castro Conde, A. Impacto del consenso español para la mejora de los objetivos LDL colesterol después de un síndrome coronario agudo.

Type: Estudios, phase No EPA.

HULP code: PI-4420.

Sponsored's protocol code: GOAL.

Sponsored by: Sociedad Española de Cardiología.

Signed date: 10/11/2020

Escobar Cervantes, C. Tratamiento de pacientes dislipémicos con alto riesgo y muy alto riesgo para la prevención de eventos

cardiovasculares en Europa. Estudio multinacional observacional (Santorini).

Type: Estudios, phase EPA-SP.

HULP code: PI-4163A.

Sponsored's protocol code: DSE-

HCL-01-19.

Sponsored by: Daiichi-Sankyo Europe GmbH.

Signed date: 12/06/2020

Iniesta Manjavacas, AM. Estudio observacional ambispectivo para analizar el manejo evolutivo de los fármacos con efecto pronóstico en pacientes tratados con polipíldora como tratamiento de base al alta de un primer síndrome coronario agudo.

Type: Estudios, phase EPA-SP.

HULP code: PI-4368.

Sponsored's protocol code: PANDORA FER-AAS-2020-0.

Sponsored by: Ferrer Internacional S.A.

Signed date: 28/09/2020

López De Sá Areses, E. Estudio en fase IIB, aleatorizado, doble ciego controlado con placebo, de grupos paralelos para evaluar la eficacia y la seguridad de Medi6570 en participantes con infarto de miocardio previo, inflamación persistente y niveles elevados de prohormona N-terminal natriurético cerebral.

Type: EECC, phase II.

HULP code: 5637.

Sponsored's protocol code:

D4920C00002.

Sponsored by: Astrazeneca Ab.

Signed date: 28/09/2020

López-Sendón Hentschel, JL. Detección precoz de isquemia miocárdica compatible con síndrome coronario agudo mediante APO J-GLIC como un nuevo biomarcador de isquemia.

Type: Estudios, phase No EPA.

HULP code: Anexo 1 PI-3647.

Sponsored's protocol code: EDICA-2019.

Sponsored by: Glycardial Diagnostics S.L.

Signed date: 20/01/2020

López-Sendón Hentschel, JL. Detección precoz de isquemia miocárdica compatible con síndrome coronario agudo mediante APO J-GLYC como un nuevo biomarcador de isquemia.

Type: Estudios, phase No EPA.

HULP code: Anexo 2 PI-3647.

Sponsored's protocol code: EDICA-2019.

Sponsored by: Glycardial Diagnostics S.L.

Signed date: 09/07/2020

Merino Llorens, JL. Estudio observacional para evaluar el manejo clínico y la adecuación de las estrategias terapéuticas utilizadas en pacientes con enfermedad aterosclerótica estable y el uso de los tratamientos recomendados de acuerdo a las guías clínicas. Estudio Apalusa.

Type: Estudios, phase EPA-OD.

HULP code: PI-3815B.

Sponsored's protocol code: SEC-

ATE-2019-01.

Sponsored by: Sociedad Española de Cardiología.

Signed date: 14/07/2020

Moreno Gómez, JL. Estudio post-autorización trevisio: estudio multicéntrico, no aleatorizado y de un solo grupo del Amplatzer™ Trevisio™ intravascular delivery system para facilitar la implantación percutánea y transcatheter de los oclusores amplatzer.

Type: Estudios, phase Producto Sanitario.

HULP code: PI-4379B.

Sponsored's protocol code: CRD-963/ABT-

CIP-10319.

Sponsored by: Abbott Medical España S.A.

Signed date: 23/10/2020

Pérez Valero, I. Estudio de fase III, aleatorizado, multicéntrico, abierto y de no-inferioridad para evaluar la eficacia, la seguridad y la tolerabilidad del cambio de tratamiento

a una combinación en dosis fijas de dolutegravir/lamivudina en adultos infectados por el VIH-1 con supresión virológica.

Type: EECC, phase III.

HULP code: Anexo 1 5354.

Sponsored's protocol code:

Sponsored by: VIIV Healthcare Uk Limited.

Signed date: 02/07/2020

Riera Del Moral, LF. Ensayo clínico multicéntrico, aleatorizado, de búsqueda de dosis, de grupos paralelos, doble ciego y controlado con placebo, para evaluar la seguridad y eficacia de la administración intramuscular de células mesenquimales-allogénicas derivadas de tejido adiposo en pacientes diabéticos con isquemia crítica de miembros inferiores sin posibilidad de revascularización.

Type: Estudios, phase No EPA.

HULP code: 5426.

Sponsored's protocol code: NOMA.

Sponsored by: Instituto Investigación Sanitaria Fjd.

Signed date: 18/06/2020

Patents and trademarks

Filgueiras Rama D, López de Sá y Areses E, Millet Roig J, Calvo Saiz CJ, inventors; Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), FIBHULP, Universidad Politécnica de Valencia, assignees. Method of predicting or prognosticating neurological performance in patients who have suffered a cardiac arrest and optionally comatose status due to ventricular fibrillation. PCT/EP2015/076893, EP3020333; 2014 November 17.

Riera del Moral LF, inventor; FIBHULP, assignee. Aortic endoprosthesis for the treatment of aneurysm. P201231638, PCT/ES2013/070712; 2012 October 24.